Oscar health doubles outlook, but investors remain skeptical

The operating change is clearest in how Oscar now talks about earnings: not as a byproduct of growth, but as the result of tighter underwriting and medical cost control. On the New York Stock Exchange in September, management said “we increased our 2026 guidance by hund00 million… we’ve actually doubled um our expectation for our earnings this year,” because “utilization… is moving… favorable to what we had expected for the full year,” while adding that “50 basis points for us is about $und00 million and that’s what’s driving the performance in the guide race that we had today.”

That discipline is showing up in the mechanics of the business as well: Oscar defined medical loss ratio as “a way to dimension how much we’re spending on medical expenses for our members versus our revenue,” adding, “For every dollar of revenue I collect, I’m spending around 81 a.5 cents” on care, and tied better cost trends directly to profitability. The same operating rigor appears in technology-enabled execution, with an automated claims engine posting a “98.7% first pass accuracy rate” and “resolving most reviews in under 48 hours,” while Oscar says its “net promoter score is in the 40 to 50 range,” which “massively lowers their customer acquisition costs compared to peers” because “People stay and they refer friends.”

Oscar’s growth case is no longer just about adding more exchange members; it is about making the exchange model travel into adjacent channels. Marc Bertolini said the company is trying to “make the market bigger” by recreating the ACA model for employers shifting to defined-contribution benefits, while leaning on network breadth as an enabler: “we have 73% of all the physicians in the country on our network,” he said, adding that “There’s over 100 in the ACA today,” a range of options that supports consumer choice without abandoning provider continuity.

That broader engine is already taking shape through Lucie, CHOICE and specialized plans that widen Oscar’s addressable market beyond its core exchange book. Bertolini said of the shared-network launch, “we just launched… It’s about 600,000 now, but we think it’ll be two and a half million by 29,” while Fierce Healthcare reported Oscar is “growing the number of counties in its geographic footprint by 24% in 2027,” offering plans across “713 counties in 21 states,” as HelloMeno expands to 15 states and Oscar’s ICHRA plans, “rebranded as Custom Health Option and Individual Care Expense, or CHOICE,” let employers fund exchange shopping directly.

The valuation debate is visible not just in models but in trading behavior. Yahoo Finance captured the shift bluntly in the headline, “Oscar Health Slides 7% to $30.99 as insiders sell $138 M, sparking valuation concerns,” and the scale matters: insiders were reported to be selling “$138 M,” while the stock “Slides 7% to $30.99,” a reaction that suggests investors did not treat stronger fundamentals as enough to settle fair-value questions and instead read insider monetization as a signal that the stock may already discount much of the good news.

Institutional positioning and valuation frameworks point in the same direction: uncertainty over whether the shares deserve their price. ETF flow analysis showed how quickly sentiment can reverse—“One week gets $986.85M in inflows. The next week, $462.73M in outflows,” with the “same authorized participants are creating and redeeming shares in both directions”—while Simply Wall St noted, “On that yardstick, Oscar trades on a P/E of 17.1x,” and concluded that “the Fair Ratio framework… points to the current 17.1x sitting below the multiple you might expect for this business,” leaving the stock caught between skepticism and a case for undervaluation.